Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals, a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2015, the company focuses on developing innovative therapies for patients with significant unmet medical needs, particularly in the areas of autoimmune and rare diseases. Kiniksa's core products, including its lead asset, are designed to address complex health challenges, setting them apart through their unique mechanisms of action. The company has achieved notable milestones, including successful clinical trials that underscore its commitment to advancing patient care. With a strong market position, Kiniksa Pharmaceuticals continues to make strides in the biopharmaceutical landscape, driven by a dedication to scientific excellence and patient-centric solutions.
DitchCarbon Score
How does Kiniksa Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kiniksa Pharmaceuticals's score of 26 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kiniksa Pharmaceuticals's reported carbon emissions
Kiniksa Pharmaceuticals, headquartered in the US, currently does not have publicly available data on its carbon emissions, as no specific emissions figures have been reported. Additionally, there are no documented reduction targets or climate pledges outlined by the company. This lack of information suggests that Kiniksa Pharmaceuticals may still be in the early stages of developing a comprehensive climate strategy or reporting framework. As the pharmaceutical industry increasingly prioritises sustainability and climate commitments, it will be important for Kiniksa to establish clear targets and initiatives to address its carbon footprint in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kiniksa Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
